An announcement from Dyne Therapeutics ( (DYN) ) is now available.
Dyne Therapeutics has reported promising clinical data from its Phase 1/2 ACHIEVE trial of DYNE-101, targeting myotonic dystrophy type 1 (DM1), showing significant improvements in disease biomarkers and functional endpoints. The company plans a global Registrational Expansion Cohort to support a U.S. Accelerated Approval submission in 2026, highlighting the potential of DYNE-101 to transform treatment paradigms for DM1. Additionally, in the DELIVER trial for DYNE-251, targeting Duchenne muscular dystrophy, the company revealed favorable safety data and plans to pursue accelerated approval pathways, with submissions expected early in 2026.
More about Dyne Therapeutics
Dyne Therapeutics is a clinical-stage company focusing on developing treatments for genetically driven neuromuscular diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The company is known for its FORCE platform, which is designed to deliver therapeutics to relevant tissues.
YTD Price Performance: -9.47%
Average Trading Volume: 942,019
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.35B
For detailed information about DYN stock, go to TipRanks’ Stock Analysis page.